Daihan Pharmaceutical Co.Ltd (023910) — Free Cash Flow Generation Index
Daihan Pharmaceutical Co.Ltd (023910) has a Free Cash Flow Generation Index of -0.14x as of September 2025. Free cash flow of ₩-1.32 Billion represents 0% of operating cash flow (₩9.47 Billion). Explore Daihan Pharmaceutical Co.Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Daihan Pharmaceutical Co.Ltd Free Cash Flow Generation Index (2014–2024)
Historical FCF Generation Index trend for Daihan Pharmaceutical Co.Ltd across 11 annual periods. For the full cash flow conversion analysis, see Daihan Pharmaceutical Co.Ltd operating cash flow efficiency.
Annual Free Cash Flow Generation for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year Free Cash Flow Generation Index for Daihan Pharmaceutical Co.Ltd. Check 023910 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.56x | ₩19.84 Billion | ₩35.64 Billion | ₩15.80 Billion | ▲ +23.1% |
| 2023 | 0.45x | ₩17.58 Billion | ₩38.86 Billion | ₩21.28 Billion | ▼ -35.6% |
| 2022 | 0.70x | ₩20.38 Billion | ₩29.00 Billion | ₩8.62 Billion | ▼ -0.8% |
| 2021 | 0.71x | ₩28.77 Billion | ₩40.62 Billion | ₩11.85 Billion | ▼ -15.7% |
| 2020 | 0.84x | ₩28.27 Billion | ₩33.63 Billion | ₩5.36 Billion | ▼ -43.6% |
| 2019 | 1.49x | ₩52.57 Billion | ₩35.26 Billion | ₩17.30 Billion | ▼ -26.9% |
| 2018 | 2.04x | ₩91.63 Billion | ₩44.94 Billion | ₩46.69 Billion | ▲ +0.5% |
| 2017 | 2.03x | ₩41.50 Billion | ₩20.45 Billion | ₩21.05 Billion | ▲ +13.7% |
| 2016 | 1.78x | ₩49.82 Billion | ₩27.92 Billion | ₩21.90 Billion | ▲ +46.2% |
| 2015 | 1.22x | ₩21.94 Billion | ₩17.98 Billion | ₩3.96 Billion | ▼ -42.0% |
| 2014 | 2.10x | ₩19.95 Billion | ₩9.48 Billion | ₩10.47 Billion | — |